Lung transplant for interstitial lung disease

Clinical Pulmonary Medicine

Volumn 7, Issue 4, 2000, Pages 178-186

  Meyer, Keith C ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Idiopathic pulmonary fibrosis; Interstitial lung disease; Lung transplantation; Sarcoidosis

Indexed keywords

ALLERGIC PNEUMONITIS; ARTICLE; CAUSE OF DEATH; EOSINOPHILIC GRANULOMA; GAS EXCHANGE; HUMAN; INTERSTITIAL LUNG DISEASE; LEIOMYOMATOSIS; LUNG FIBROSIS; LUNG TRANSPLANTATION; OCCUPATIONAL EXPOSURE; PATIENT REFERRAL; PNEUMOCONIOSIS; PREOPERATIVE EVALUATION; PROGNOSIS; QUALITY OF LIFE; RECURRENT DISEASE; RESPIRATORY FAILURE; SARCOIDOSIS; SURVIVAL RATE;

EID: 0033854921     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045413-200007040-00003     Document Type: Article

References (50)

1. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L, A preliminary study of long-term treatment with interferon γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341: 1264-9.
2. Raghu G, Johnson C, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999;159: 1061-9.
3. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980;35:171-80.
4. Schwartz DA, Helmers RA, Galvin JR, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149:450-4.
5. Hanson D, Winterbauer RH, Kirtland SH, Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995;108:305-10.
6. International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/ American Thoracic Society (ATS)/European Respiratory Society (ERS)/International Society for Heart and Lung Transplantation (ISHLT). Am J Respir Crit Care Med 1998;158: 335-9.
7. Katzenstein A, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157:1301-15.
8. Mason RJ, Schwarz MI, Hunninghake GW, Musson RA. Pharmacological therapy for idiopathic pulmonary fibrosis: past, present, and future. Am J Respir Crit Care Med 1999;160: 1771-7.
9. Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE, Godwin JD. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 1999;116: 1168-74.
10. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994;150: 967-72.
11. Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ 1990;301:1015-7.
12. Crystal RG, Bitterman PB, Rennard SI, Hance AJ, Keogh BA. Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 1984;310:154-66, 235-44.
13. Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998; 113:396-400.
14. Carrington CG, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978;298:801-8.
15. Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994;149:1583-90.
16. Nagai S, Kitaichi M, Hamada K, et al. Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF. Sarcoidosis Vase Diffuse Lung Dis 1999;16: 209-14.
17. Douglas WW, Ryu JH, Swensen J, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis: a randomized prospective study. Am J Respir Crit Care Med 1998;158:220-5.
18. Meyer KC, Raghu G. Perspectives and future advances on the diagnosis and treatment of idiopathic pulmonary fibrosis. In: Lenfant C, editor. Biology of the lung. New York: Marcel Dekker, Inc, 1995:837-74.
19. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Mod 1997;17:1224-34.
20. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:149-73.
21. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997;145:234-41.
22. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy. Chest 1997;111:623-31.
23. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid therapy. Thorax 1996; 51:238-47.
24. Delobbe A, Durieu J, Duhamel A, Wallaert B. Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Eur Respir J 1996;9:2002-6.
25. Carrington CB, Cugell DW, Gaensler EA, et al. Lymphangioleiomyomatosis. Physiologic-pathologic-radiologic correlations. Am Rev Respir Dis 1977;116:977-95.
26. Taylor JR, Ryu J, Colby TV, et al. Lymphangioleiomyomatosis: clinical course in 32 patients. N Engl J Med 1990;323:1254-60.
27. Eliasson AH, Phillips YY, Tenholder MF. Treatment of lymphangioleiomyomatosis. Chest 1989;196:1352-5.
28. Eisenberg H. The interstitial lung diseases associated with the collagen-vascular disorders. Clin Chest Med 1982;3:565-78.
29. Black L, Katz S. Respiratory disease: task force report on prevention, control, education. Bethesda, MD: US Department of Health, Education, and Welfare; Public Health Service; National Institutes of Health. DHEW Publication No. 1977:77-1248.
30. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis: a population-based cohort study. Am J Respir Crit Care Med 2000;161:5-8.
31. Meyer KC, Love RB, Zimmerman JJ. The therapeutic potential of nitric oxide in lung transplantation. Chest 1998;113:1360-71.
32. Nunley DR, Hattler B, Keenan RJ, et al. Lung transplantation for end-stage pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:93-100.
33. Walker S, Mikhail G, Banner N, et al. Medium term results of lung transplantation for end stage pulmonary sarcoidosis. Thorax 1998;53: 281-4.
34. Nonn RA, Garrity ER Jr. Lung transplantation for fibrotic lung diseases. Am J Med Sci 1998; 315:126-54.
35. Muller C, Briegel J, Haller M, et al. Sarcoidosis recurrence following lung transplantation. Transplantation 1996;61:1117-9.
36. Kazerooni EA, Jackson C, Cascade PN. Sarcoidosis: recurrence of primary disease in transplanted lungs. Radiology 1994;192:461-4.
37. Martinez FJ, Orens JB, Deeb M, Brunsting LA, Flint A, Lynch JP 3rd. Recurrence of sarcoidosis following bilateral allogeneic lung transplantation. Chest 1994;106:1597-9.
38. Heatly T, Sekela M, Berger R. Single lung transplantation involving a donor with documented pulmonary sarcoidosis. J Heart Lung Transplant 1994;13:720-3.
39. Habib SB, Congleton J, Carr D, et al. Recurrence of recipient Langerhans' cell histiocytosis following bilateral lung transplantation. Thorax 1998;53:323-5.
40. Etienne B, Bertocchi M, Gamondes JP, et al. Relapsing pulmonary Langerhans cell histiocytosis after lung transplantation. Am J Respir Crit Care Med 1998;157:288-91.
41. Bittmann I, Dose TB, Muller C, Dienemann H, Vogelmeier C, Lohrs U. Lymphangioleiomyomatosis: recurrence after single lung transplantation. Hum Pathol 1997;28:1420-3.
42. O'Brien JD, Lium JH, Parosa JF, Deyoung BR, Wick MR, Trulock EP. Lymphangiomyomatosis recurrence in the allograft after single-lung transplantation. Am J Respir Crit Care Med 1995;151:2033-6.
43. Frost AE, Keller CA, Brown RW, et al. Giant cell interstitial pneumonitis. Disease recurrence in the transplanted lung. Am Rev Respir Dis 1993;148:1401-4.
44. Robinson DS, Geddes DM, Hansell DM, et al. Partial resolution of acute interstitial pneumonia in native lung after single lung transplantation. Thorax 1996;51:1158-9.
45. Lok SS, Smith E, Doran HM, Sawyer R, Yonan N, Egan JJ. Idiopathic pulmonary fibrosis and cyclosporine: a lesson from single lung transplantation. Chest 1998;114:1478-81.
46. Verleden GM, Sels F, van Raemdonck D, Verbeken EK, Lerut T, Demedts M. Possible recurrence of desquamative interstitial pneumonitis in a single lung transplant recipient. Eur Respir J 1998;11:971-4.
47. King MB, Jessurun J, Hertz MI. Recurrence of desquamative interstitial pneumonia after lung transplantation. Am J Respir Crit Care Med 1997;156:2003-5.
48. Gabbay E, Dark JH, Ashcroft T, Corris PA. Cryptogenic organizing pneumonia is an important cause of graft dysfunction and should be included in the classification of pulmonary allograft rejection. J Heart Lung Transplant 1998;17:230-1.
49. Siddiqui MT, Garrity ER, Husain AN. Bronchiolitis obliterans organizing pneumonia-like reactions: a nonspecific response or an atypical form of rejection or infection in lung allograft recipients? Hum Pathol 1996;27:714-9.
50. 1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998;66:1014-20.